Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 10/20 | 0.94 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.94 |
| ▸ | TSHR | P16473 | 3/20 | 0.94 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.94 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.94 |
| ▸ | HPGD | P15428 | 2/20 | 0.94 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.94 |
| ▸ | MEN1 | O00255 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.94 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.94 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.94 |
| ▸ | RARB | P10826 | 1/20 | 0.94 |
| ▸ | RARG | P13631 | 1/20 | 0.94 |
| ▸ | DRD1 | P21728 | 1/20 | 0.94 |
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.94 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11854096 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL13399727 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL10198573 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23353103 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL13649331 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23352620 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23353047 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23352905 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL22425786 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL5436690 | 0.97 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246932-B2 | Prostaglandin compositions and methods for the treatment of vasospasm | NEXMED HOLDINGS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20190076529-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20150272875-A1 | ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION | NEXMED HOLDINGS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150272875-A1 | ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION | NEXMED HOLDINGS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9066854-B2 | Alprostadil and dyclonine for treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9066854-B2 | Alprostadil and dyclonine for treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9060929-B2 | Alprostadil for treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9060929-B2 | Alprostadil for treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9056044-B2 | Alprostadil and lidocaine treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056044-B2 | Alprostadil and lidocaine treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140213654-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213654-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140206766-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206766-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140142188-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142188-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8632813-B2 | Prostaglandin compositions and methods for the treatment of vasospasm | NEXMED (HOLDINGS), INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8632813-B2 | Prostaglandin compositions and methods for the treatment of vasospasm | NEXMED (HOLDINGS), INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20080069883-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080069883-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076529-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | PTGIS, PTGIR, PGF | PTGIR 2/4885PTGER2 11/4885TSHR 2900/4885 |
| US-20140142188-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | PTGIS, PTGIR, PGF | PTGIR 2/4885PTGER2 11/4885TSHR 2900/4885 |
| US-20140206766-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | PTGIS, PTGIR, PGF | PTGIR 2/4885PTGER2 11/4885TSHR 2900/4885 |
| US-11246932-B2 | Prostaglandin compositions and methods for the treatment of vasospasm | PTGIS, PTGIR, PGF | PTGIR 2/4885PTGER2 11/4885TSHR 2900/4885 |
| US-20080069883-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | PTGIS, PTGIR, PGF | PTGIR 2/4885PTGER2 11/4885TSHR 2900/4885 |
| US-20150272875-A1 | ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION | PTGER1, PLA2G10, PDE12 | PTGIR 74/4885PTGER2 14/4885TSHR 4590/4885 |
| US-20140213654-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | PTGIS, PTGIR, PGF | PTGIR 2/4885PTGER2 11/4885TSHR 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.